k
you sound familiar
not related to tobago/tharlow...?
Bayer says Nexavar phase III skin cancer tests fail to meet primary endpoint
bayer LEVERKUSEN, Germany (AFX) - Bayer (nyse: BAY ) AG and Onyx Pharmaceuticals Inc said Phase III skin cancer tests of their Nexavar (sorafenib) tablets failed to meet their primary endpoint of improving progression-free survival (PFS).